WO2016006974A3 - Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof - Google Patents

Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof Download PDF

Info

Publication number
WO2016006974A3
WO2016006974A3 PCT/KR2015/007219 KR2015007219W WO2016006974A3 WO 2016006974 A3 WO2016006974 A3 WO 2016006974A3 KR 2015007219 W KR2015007219 W KR 2015007219W WO 2016006974 A3 WO2016006974 A3 WO 2016006974A3
Authority
WO
WIPO (PCT)
Prior art keywords
triazolopyrimidinone
novel
triazolopyridinone
derivatives
triazolopyridinone derivatives
Prior art date
Application number
PCT/KR2015/007219
Other languages
French (fr)
Other versions
WO2016006974A2 (en
Inventor
Jung Nyoung Heo
Hwan Jung LIM
Kwang Rok Kim
Kyung Jin Kim
Uk Il Kim
Hyung Tae Bang
Ji Hye Yoon
Original Assignee
St Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150068375A external-priority patent/KR101739003B1/en
Application filed by St Pharm Co., Ltd. filed Critical St Pharm Co., Ltd.
Priority to ES15818399T priority Critical patent/ES2763566T3/en
Priority to PL15818399T priority patent/PL3166945T3/en
Priority to DK15818399.6T priority patent/DK3166945T3/en
Priority to EP15818399.6A priority patent/EP3166945B1/en
Priority to JP2017501285A priority patent/JP6257835B2/en
Priority to CN201580037780.XA priority patent/CN106488918B/en
Priority to US15/325,651 priority patent/US9914737B2/en
Publication of WO2016006974A2 publication Critical patent/WO2016006974A2/en
Publication of WO2016006974A3 publication Critical patent/WO2016006974A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
PCT/KR2015/007219 2014-07-11 2015-07-10 Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof WO2016006974A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES15818399T ES2763566T3 (en) 2014-07-11 2015-07-10 Novel derivatives of triazolopyrimidinone or triazolopyridinone, and use
PL15818399T PL3166945T3 (en) 2014-07-11 2015-07-10 Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
DK15818399.6T DK3166945T3 (en) 2014-07-11 2015-07-10 HIS UNKNOWN TRIAZOLOPYRIMIDINON OR TRIAZOLOPYRIDINE DERIVATIVES AND USE THEREOF
EP15818399.6A EP3166945B1 (en) 2014-07-11 2015-07-10 Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
JP2017501285A JP6257835B2 (en) 2014-07-11 2015-07-10 Novel triazolopyrimidinone or triazolopyridinone derivatives and their uses
CN201580037780.XA CN106488918B (en) 2014-07-11 2015-07-10 Triazolopyrimidone or triazolopyridinone derivatives and uses thereof
US15/325,651 US9914737B2 (en) 2014-07-11 2015-07-10 Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2014-0087798 2014-07-11
KR20140087798 2014-07-11
KR1020150068375A KR101739003B1 (en) 2014-07-11 2015-05-15 Novel triazolopyrimidinone or triazolopyridone derivatives, and use thereof
KR10-2015-0068375 2015-05-15

Publications (2)

Publication Number Publication Date
WO2016006974A2 WO2016006974A2 (en) 2016-01-14
WO2016006974A3 true WO2016006974A3 (en) 2016-07-21

Family

ID=55065060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/007219 WO2016006974A2 (en) 2014-07-11 2015-07-10 Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof

Country Status (1)

Country Link
WO (1) WO2016006974A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6923138B2 (en) * 2016-06-30 2021-08-18 国立研究開発法人理化学研究所 New compound or pharmacologically acceptable salt thereof
JP7076741B2 (en) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 BMP signal inhibitor compound
EP3733206A4 (en) * 2017-12-27 2021-12-01 Japanese Foundation For Cancer Research Anticancer agent
WO2023101048A1 (en) * 2021-12-01 2023-06-08 에스티팜 주식회사 Method for preparing triazolopyrimidinone derivative

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071650A2 (en) * 2006-12-11 2008-06-19 Galapagos N.V. Novel compounds useful for the treatment of degenerative & inflammatory diseases
WO2013143663A1 (en) * 2012-03-28 2013-10-03 Merck Patent Gmbh Bicyclic pyrazinone derivatives
WO2013182580A1 (en) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2013182546A1 (en) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
KR20140051944A (en) * 2011-07-13 2014-05-02 노파르티스 아게 4-piperidinyl compounds for use as tankyrase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071650A2 (en) * 2006-12-11 2008-06-19 Galapagos N.V. Novel compounds useful for the treatment of degenerative & inflammatory diseases
KR20140051944A (en) * 2011-07-13 2014-05-02 노파르티스 아게 4-piperidinyl compounds for use as tankyrase inhibitors
WO2013143663A1 (en) * 2012-03-28 2013-10-03 Merck Patent Gmbh Bicyclic pyrazinone derivatives
WO2013182580A1 (en) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2013182546A1 (en) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase

Also Published As

Publication number Publication date
WO2016006974A2 (en) 2016-01-14

Similar Documents

Publication Publication Date Title
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
EP4071149A3 (en) Heterocyclic compounds and uses thereof
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
EP3895717A4 (en) Pharmaceutical composition for preventing or treating cancer, comprising weissella cibaria wikim28 as active ingredient
EP3613419A4 (en) Pharmaceutical composition containing indirubin derivative as active ingredient
PH12016502246A1 (en) Carboxamide derivatives
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
EP3248603A4 (en) Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient
WO2015001541A3 (en) Pharmaceutical film composition
MX2019008338A (en) Pharmaceutical composition containing sulglycotide or pharmaceutically acceptable salt thereof for preventing or treating dry eye.
EA201691741A1 (en) PHARMACEUTICAL COMPOSITION
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
WO2016163818A3 (en) Pharmaceutical composition for preventing or treating arthritis or inflammatory disease containing 2-methoxy-4-(3-(4-methoxyphenyl)propyl-1-en-1-yl)phenol as active ingredient
WO2016020408A3 (en) Compounds for preventing ototoxicity
JOP20180071A1 (en) CJ Healthcare Corporation
EP3404020A4 (en) Pyridinol derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15818399

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017501285

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15325651

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015818399

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015818399

Country of ref document: EP